Effects of perioperative rosuvastatin on postoperative delirium in elderly patients:A randomized,double-blind,and placebo-controlled trial
作者机构：Department of AnesthesiologyWuxi Clinical College of Anhui Medical University904th Hospital of Joint Logistic Support Force of PLAWuxi Clinical College of Anhui Medical UniversityWuxi 214044Jiangsu ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2021年第9卷第21期
页 面：5909-5920页
核心收录：
学科分类：1002[医学-临床医学] 100217[医学-麻醉学] 10[医学]
主 题：Perioperative rosuvastatin Postoperative delirium Elderly General anesthesia Randomised controlled trial
摘 要：BACKGROUND Experimental evidence has indicated the benefits of statins for the treatment of postoperative ***,clinical trials did not reach definite conclusions on the effects of statins on *** clinical trials have indicated that statins reduce postoperative delirium and improve outcomes,while some studies have reported negative *** To evaluate whether perioperative rosuvastatin treatment reduces the incidence of delirium and improves clinical *** This randomized,double-blind,and placebo-controlled trial was conducted in a single center in Jiangsu,*** study enrolled patients aged greater than 60 years who received general anesthesia during elective operations and provided informed consent.A computer-generated randomization sequence(in a 1:1 ratio)was used to randomly assign patients to receive either rosuvastatin(40 mg/d)or ***,care providers,and investigators were all masked to group *** primary endpoint was the incidence of delirium,which was assessed twice daily with the Confusion Assessment Method during the first 7 postoperative *** were performed on intention-to-treat and safety *** Between January 1,2017 and January 1,2020,3512 patients were assessed.A total of 821 patients were randomly assigned to receive either placebo(n=411)or rosuvastatin(n=410).The incidence of postoperative delirium was significantly lower in the rosuvastatin group[23(5.6%)of 410 patients]than in the placebo group{42(13.5%)of 411 patients[odds ratios(OR)=0.522,95%confidence interval(CI):0.308-0.885;P0.05]}.No significant difference in 30-d all-cause mortality(6.1%vs 8.7%,OR=0.67,95%CI:0.39-1.2,P=0.147)was observed between the two *** decreased the hospitalization time(13.8±2.5 vs 14.2±2.8,P=0.03)and hospitalization expenses(9.3±2.5 vs 9.8±2.9,P=0.007).No significant differences in abnormal liver enzymes(9.0%vs 7.1%,OR=1.307,95%CI:0.787-2.169,P=0.30)or rhabdomyol
维普期刊数据库